Neumora Therapeutics, Inc. (NMRA)
| Market Cap | 370.94M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -236.30M |
| Shares Out | 167.09M |
| EPS (ttm) | -1.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 472,285 |
| Open | 2.270 |
| Previous Close | 2.275 |
| Day's Range | 2.210 - 2.300 |
| 52-Week Range | 0.611 - 11.570 |
| Beta | 3.16 |
| Analysts | Buy |
| Price Target | 8.00 (+260.36%) |
| Earnings Date | Nov 6, 2025 |
About NMRA
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease. In a... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for NMRA stock is "Buy." The 12-month stock price target is $8.0, which is an increase of 260.36% from the latest price.
News
Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline
RBC Capital Markets upgraded Neumora Therapeutics, Inc. (NASDAQ: NMRA) from Sector Perform to Outperform, with an increased price forecast from $4 to $7.
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Announced class-leading data from diet-induced obesity (DIO) mouse model with NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor, and expect to initiate Phase 1 study ...
Neumora Therapeutics to Participate in Upcoming Conferences in November
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that...
Neumora Therapeutics, Inc. (NMRA) Discusses NMRA-215 Preclinical Results and Portfolio Updates, Including Obesity and Alzheimer's Disease Programs Transcript
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Discusses NMRA-215 Preclinical Results and Portfolio Updates, Including Obesity and Alzheimer's Disease Programs October 27, 2025 8:00 AM EDT Company Particip...
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora's M4 franchise; both programs have potential best-in-class pharmacology
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction NMRA-215 demonstrated best-in-class weight loss of up to 26% in combination with semaglut...
Neumora Therapeutics to Host Virtual R&D Day on October 27
WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that...
Neumora Therapeutics to Participate in Upcoming Conferences in September
WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs tha...
Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call Transcript
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Daljit Singh Aurora - Corporate Participant Chief Operationg & Development off...
Neumora (NMRA) Q2 Loss Improves 10%
Neumora Therapeutics (NMRA -4.22%), a clinical-stage neuroscience company developing targeted therapies for brain diseases, released its second quarter 2025 results on August 6, 2025. The most signifi...
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces prioriti...
Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
WATERTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease...
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile No convulsions observed in pre-clinical studies conducted in multiple species, including rabbit...
Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Q1 2025 Results Conference Call May 12, 2025 4:30 PM ET Company Participants Helen Rubinstein - Vice President of Investor Relations & Communications Paul Ber...
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
On track to report topline data from NMRA-511 in Alzheimer's disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major ...
Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
WATERTOWN, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain diseas...
NMRA Deadline: NMRA Investors with Losses in Excess of $100K Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm
NEW YORK , April 4, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to...
NMRA Deadline: NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm
NEW YORK , March 30, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable t...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in Neumora Therapeutics, Inc. Lawsuit - NMRA
NEW YORK , March 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA). Shareholders who purchased shares of NMRA during ...
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm
NEW YORK , March 26, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable t...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Neumora To Contact Him Directly To Discuss Their Options
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Neumora To Contact Him Directly To Discuss Their Options If you purchased or acquire...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in Neumora Therapeutics, Inc. Lawsuit – NMRA
NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA).
Neumora Therapeutics to Present at Leerink Global Healthcare Conference
WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and...
Neumora Therapeutics, Inc. (NMRA) Q4 2024 Earnings Call Transcript
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Q4 2024 Results Conference Call March 3, 2025 8:00 AM ET Company Participants Helen Rubinstein - Vice President of Investor Relations & Communications Paul Be...